Biogen and Bio-Thera Reveal Tocilizumab Progress

Biosimilar Actemra Phase III Results Trigger $30m Payment Under April Deal

 
• By David Wallace
Tocilizumab Syringe Hand Glove
Biogen and Bio-Thera have announced Phase III results for their Actemra biosimilar • Source: Alamy

More from Biosimilars

More from Products